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Coccidioides is a fungal pathogen of humans which can cause a life-threatening
respiratory disease in immunocompetent individuals. Recurrent epidemics of
coccidioidal infections in Southwestern United States has raised the specter of
awareness of this soil-borne microbe, particularly among residents of Arizona and
Southern California, and has galvanized research efforts to develop a human
vaccine against coccidioidomycosis. In this review, we discuss the rationale for such
a vaccine, examine the features of host innate and acquired immune response to
Coccidioides infection, describe strategies used to identify and evaluate vaccine
candidates, and provide an update on progress toward development of a vaccine
against this endemic pathogen.
Introduction
Coccidioides is the etiologic agent of a human respira-
tory infection known as coccidioidomycosis or San
Joaquin Valley fever [1]. The clinical manifestations of
this disease range from an influenza-like illness that
resolves spontaneously, to a hematogenously and
lymphogenously disseminated mycosis in which the
pathogen can migrate from the lungs to the skin,
bone, meninges and, in some cases, even to the
peritoneum, heart and multiple other body organs
[2],[3]. About half of the Coccidioides -infected indivi-
duals experience only mild discomfort and do not seek
medical intervention. On the other hand, these same
individuals could be at risk of reactivation of cocci-
dioidal infection later in life if they contract an
immunocompromising disease or undergo organ trans-
plantation with elective immunosuppression 4/8. Re-
activation of Coccidioides infection may occur in
pregnant women during their third trimester [9], when
it has been shown that the risk of dissemination of the
fungal pathogen is highest [10]. An intriguing case of
coccidioidomycosis has been reported in which a
concomitant bacterial and viral infection apparently
predisposed the individual to reactivation of the fungal
infection [11].
Approximately half of the presumably immunocom-
petent individuals exposed to Coccidioides develop
symptomatic infection, which manifests one to four
weeks after inhalation of the fungal spores. The disease
at this stage is an atypical pneumonia, characterized by
such conditions as pleuritic chest pain, cough, fever,
malaise, rashes, mild sore throat, headache, arthralgia,
myalgia, or anorexia [12]. Most infected individuals
recover during the subsequent few weeks to several
months, while approximately 5 to 10 percent show
evidence of active disease based on positive results of
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serology and chest radiographs. Detection of rising
titers of patient immunoglobulin G (IgG) antibody to
Coccidioides antigen provides a definitive diagnosis of
active coccidioidomycosis. Microscopic examinations
of sputum or bronchoscopy specimens are used for
diagnosis of the pulmonary form of the disease. On rare
occasions, particularly in patients with acquired im-
munodeficiency syndrome (AIDS), the results of
bronchoscopic and serologic tests for Coccidioides
infection are negative or inconclusive, making differ-
ential diagnosis of the disease problematic [13]. Patients
who present with any of the primary symptoms of
pulmonary infection described above, as well as posi-
tive chest radiographs and enlarged lymph nodes
composed of caseating granulomas, are not necessarily
infected with Coccidioides. There is a close similarity
between the clinical presentations of coccidioidomyco-
sis and tuberculosis, including caseating granulomas
which are observed in both pulmonary diseases [14].
The most reliable evidence of coccidioidal infection is
positive identification of the pathogen in cultures of
sputum, bronchoalveolar lavage fluids (BALFs) or
tissue biopsies obtained from patients with active
disease.
Antifungal drug treatment of persons with newly
diagnosed coccidioidomycosis may hasten symptom
resolution, but physicians decide on a case-by-case
basis whether a patient’s circumstances warrant early
therapy [15]. Previous studies of patients treated with
fluconazole indicated that the relapse rate following
therapy is high (approx. 37%), and treatment trials with
higher doses of azoles were recommended [16]. Cur-
rently, an aggressive therapeutic protocol (e.g., 400 mg/
d for ketoconazole, 400 mg/d for fluconazole, or 200
mg twice daily for itraconazole) is recommended if
symptoms persist for more than 2 months. Drug
therapy is commonly maintained for at least 3 to 6
months. Coccidioidomycosis contracted by patients
infected with HIV often requires life-long antifungal
medication to suppress reactivation of the fungal
disease [17]. It has been suggested that initial treatment
of the immunosuppressed host should always be with
amphotericin B rather than an azole [18]. Azole
treatment may be used as a follow-up for patients
who respond quickly to amphotericin B. The total
yearly cost to the patient, based on a retrospective
study of 536 cases conducted between 1991 and 1993 at
the Kern Medical Center in Bakersfield, California,
was estimated at $8,096 [19]. The breakdown of
expenses was as follows: 63% attributed to hospitaliza-
tion, 18% to clinic visits, 12% to lost wages, and 7% to
the cost of drug treatment. Non-disseminated cases
averaged $5,400/year, while patients who contracted the
disseminated form of the disease faced an average cost
of $48,000. Current costs incurred by patients with
severe coccidioidal infection can climb to $300,000, and
a conservative estimate of the annual health care
expenses for treatment of patients with coccidioidomy-
cosis in the U.S. is $60 million (www.valleyfever.com).
Vaccination against Coccidioides infection has been
argued to be a cost-effective intervention [20] and, on
this basis alone, is worthy of serious consideration. In
this review, we examine the rationale and strategies
used for development of such a vaccine, describe
methods employed in the evaluation of vaccine candi-
dates, and discuss the research progress of a consortium
of investigators committed to the generation of a
human vaccine against coccidioidomycosis.
Natural reservoirs and host range
Coccidioides typically inhabits desert and semi-arid
soils where it grows as a filamentous saprobe. Fertile
hyphae of this vegetative phase give rise to dry, asexual,
air-dispersed spores (arthroconidia), which are the
infectious propagules of the pathogen [21]. A sexual
state of Coccidioides has never been observed, although
evidence has been presented that recombination (‘cryp-
tic sex’) between isolates does occur in nature [22].
Coccidioidomycosis is endemic to desert regions of
Southern California, Arizona, Nevada, New Mexico
and West Texas, as well as parts of Mexico, Central
America and South America [23,24]. Isolation of
Coccidioides from the environment has been difficult.
The organism was first cultured from soil in 1932
[25,26], but most new isolates are obtained directly
from clinical specimens. Polymerase chain reaction
(PCR) was used to amplify a Coccidioides -specific
internal transcribed spacer (ITS) of ribosomal DNA,
and employed as a probe to search for environmental
isolates [27]. However, in spite of the high sensitivity and
specificity of this assay, only 4 isolates were obtained
from a screen of 720 separate soil samples collected
from endemic areas in California. A possible explana-
tion for this is that the fungus does not survive in the
upper layers of desert soil during the hot summer
months, but instead resides in cooler, subsurface zones
which are supplied adequate nutrients for its growth. In
fact, studies have shown that greater numbers of the
organism are found several inches below the surface of
the soil where temperatures are significantly cooler [28]
and nutrients are more abundant. Large reservoirs of
bioavailable nitrogen (up to approx. 104 kilograms of
nitrogen per hectare, as nitrate) have been shown to
accumulate in the subsurface soils of desert regions and
arid shrublands which are endemic for coccidioidomy-
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cosis [29]. Burrowing rodents (kangaroo rats, pocket
mice) and armadillos have been suggested to play roles
in the harboring and spread of the pathogen in endemic
regions of North and South America [23,30] Coccidioi-
domycosis is frequently reported in domesticated dogs
that live outdoors in the Southwest [31,32]. This raises
the possibility that wild dogs, desert foxes and coyotes
may also contribute to the ecology of this environmental
pathogen. Probably all mammals residing in the en-
demic regions are at risk of coccidioidal infection
[33,34]. Death and subsequent decay of Coccidioides -
infected animals under natural conditions culminates in
conversion of the parasitic phase of the fungus into its
mycelial form, thus recharging the soil with mycelia that
yield profuse ‘arthroconidial blooms.’ Detection of
endosporulating spherules of Coccidioides in lesions
isolated from the lungs of a Sonoran Gopher snake [35]
illustrates that the pathogen is not restricted to homo-
iotherms. Casadevall and Pirofski [36] have proposed
that Coccidioides and other pathogenic, soil fungi that
cause systemic infections in humans may have alter-
native invertebrate and protozoan hosts. The authors
have argued that the virulence of these soil-inhabiting
microbes in mammalian hosts may originate from
environmental selective pressures imposed by amoeboid
and nematode predators. Foraging activities of these
microorganisms in arid soils would be restricted to brief
seasons of rainfall. Outbreaks of human infections with
Coccidioides typically follow the rainy seasons. It has
been proposed (A. Casadevall, pers. comm.) that
protozoa such as amoebae could engulf Coccidioides
cells during periods of foraging, encyst during arid
periods, and then germinate again in moist soils. This
cycle of selection for survival of the fungus in phago-
cytic cells could translate to its survival in human
macrophages. These are intriguing ideas which require
further study, first to determine whether such alter-
native hosts for Coccidioides actually occur in nature
and, if so, whether the proposed selective pressure
contributes to ‘fungal fitness’ and virulence in humans.
Genetic diversity of the pathogen
Fisher and coworkers [37] have proposed that North
American populations of Coccidioides are genetically
diverse, based on the observation that molecular
markers reveal differentiation among isolates from
California on the one hand, and Arizona and Texas
on the other [38]. It was suggested that North Amer-
ican isolates belong to two major clades, previously
designated as the Californian (CA) and non-Califor-
nian (non-CA) phylogenetic species [39,40]. Isolates
from South America, on the other hand, were shown to
be genetically less diverse and suggested to have arisen
from a single population centered in Texas. More recent
studies, which involved analyses of nucleotide sequence
diversity between microsatellite loci, have confirmed
the molecular distinction between the CA and non-CA
isolates [41], and led to formal revision of the generic
concept of Coccidioides to include two separate species
[42]. C. posadasii is a newly described taxon which
accommodates the non-CA clade and is widespread
throughout most of the endemic regions of the U.S.,
Mexico and Central and South America. C. immitis
includes the CA clade that is found primarily in the San
Joaquin Valley of California. The authors demon-
strated that C. posadasii can be distinguished from C.
immitis by numerous DNA polymorphisms, and that
microsatellite loci can be used as diagnostic markers for
this species. Although C. posadasii isolates appear to
grow slower on high salt media than C. immitis, the
morphologies of the saprobic and parasitic phases of
these two species appear to be identical. However, their
genetic distinctions may be translated into differences
in amino acid composition, antigenicity and virulence
[42]. On the basis of this supposition, two separate
genome-sequencing projects have been initiated for
Coccidioides. The genome of C. posadasii is being
sequenced at The Institute for Genomic Research
(www.tigr.org); while nucleotide sequence analysis of
C. immitis has begun at the Whitehead Institute/MIT
Center for Genome Research as part of an ambitious,
multi-genus fungal genome initiative (www.genome.
wi.mit.edu/annotation/fungi/fgi/). The genomic se-
quence of C. posadasii is essentially complete, and
annotation of the database is underway.
In vitro/in vivo morphogenesis and methods of
identification of Coccidioides
The morphology of the saprobic phase of Coccidioides
is indistinct from several closely related ascomycetous
members of the Onygenales [43/45]. Identification of
the pathogen in the past has been dependent upon both
its ability to infect mice, and the differentiation of
arthroconidia into multicellular, parasitic forms (en-
dosporulating spherules) in vitro and in vivo. Molecu-
lar methods of Coccidioides culture identification and
detection in infected host tissue are now more widely
used in clinical settings. These include the application
of commercially available chemiluminescent DNA
probe (Accuprobe) assays [Gen-Probe Inc., San Diego,
Calif.; [46]], in situ hybridization of DNA probes with
tissue sections [47], and oligonucleotide probes for PCR
amplification of pathogen-specific genes [48/50]. The
histopathology of Coccidioides infections is character-
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ized by the presence of well-defined spherules in
various stages of development, which to the trained
observer is a diagnostic feature of coccidioidomycosis.
However, human Coccidioides infections occasionally
reveal hyphal elements in surgically excised and resec-
tioned cavitary and granulomatous pulmonary lesions
in human lungs [51], which can complicate the diag-
nosis of this disease. Mycelial forms are also observed
in cutaneous lesions and in the central nervous system
of Coccidioides -infected patients. Hyphal growth in
these latter cases has been frequently associated with
plastic implants (e.g., shunts or reservoirs) used to treat
infection of the brain or cerebrospinal fluid [52].
Typically, once arthroconidia are inhaled they trans-
form into spherules in terminal bronchi and begin to
endosporulate. This sequence of morphogenetic events
can be reproduced in vitro by growth of the organism in
a defined glucose-salts medium purged with 20% CO2/
80% air [53] (Fig. 1).
Epidemiology of coccidioidomycosis
Coccidioidal infection of humans most commonly
occurs by inhalation of arthroconidia [54], although
percutaneous inoculation is also possible. It is not
known how many propagules produced by the soil-
borne, saprobic phase must be inhaled by humans to
establish symptomatic disease [55]. However, intranasal
inoculation with approximately 10 arthroconidia is
sufficient to kill BALB/c mice within 21 days post-
challenge [56]. Person-to-person transmission of Coc-
cidioides is not known to occur, except in rare cases of
maternal-fetal transfer of infected tissue [57]. Epide-
miological studies of coccidioidomycosis have revealed
that the interaction of environmental rather than
genetic factors has a major impact on recurrent
epidemics of this disease [58,59]. Important environ-
mental variables include the duration of droughts
preceding epidemics, and the timing and amounts of
rainfall following arid seasons. These factors contribute
significantly to the extent and density of the fungal
blooms in soil reservoirs. Because soil disturbance and
extensive outdoor activity enhance the chances of
infection, coccidioidomycosis is considered an occupa-
tional disease amongst agricultural and construction
workers [28]. Coccidioidomycosis is also a geographi-
cally limited disease, but the size of the resident
population in the endemic regions and the number of
visitors attracted to these parts of the nation are rapidly
growing. The population of the major endemic areas of
Southern Arizona has increased by a factor of 10 over
the past 50 years, and by a factor of 4/5 in the Central
Valley of California and West Texas. There are now
many more people at risk of coccidioidal infection than
there were 50 years ago, particularly because of the
surge in the number of ‘serologically virgin’ immigrants
[28] from the North and East. About 8 million people
live in the most highly endemic region of the South-
western United States, and millions more in the
neighboring regions of coastal Southern California.
Early reports estimated that 40% of persons infected
with Coccidioides develop symptomatic disease. Most
of these individuals (85%) present with a mild influ-
enza-like illness, while 8% may develop severe pulmon-
ary disease requiring hospitalization, and 7% develop
the disseminated extrapulmonary form of the mycosis
[60]. Risk factors for severe pulmonary and dissemi-
nated disease include African-American, Filipino or
Asian race, pregnancy, immunocompromising condi-
tions (e.g., organ transplantation, AIDS), diabetes,
smoking and older age (65 years/) [8,61/65]. Esti-
mates of the number of individuals in endemic regions
of Mexico, Central and South America who may be
subject to primary infection and are likely to develop
Fig. 1 Diagrammatic representation of the saprobic and parasitic cycles of Coccidioides posadasii (reproduced with permission from Taylor and
Francis and the American Society for Microbiology; taken from references190 (Infect. Immun) and 230 (Med. Mycol).
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severe disease are further complicated by environmen-
tal, socioeconomic, and substandard health conditions
[66]. New estimates of the percentage of people in
endemic regions who contract symptomatic coccidioi-
domycosis are based on data derived from studies of
recent outbreaks of coccidioidal infection and have
been shown to be greater than 50%. For example, 27 of
35 (77%) volunteers from Pennsylvania who traveled to
Hermosillo, Mexico to help construct a church devel-
oped an influenza-like illness within two weeks after
returning home and, based on clinical evaluations, were
all suspected to have contracted coccidioidomycosis
[60]. A similar outbreak of coccidioidal infection was
reported amongst a 126-member church group that had
traveled to Tecate, Mexico to assist in construction of
an orphanage [67]. These cases underscore the risk of
coccidioidal infection of immunocompetent individuals
who engage in construction or other activities that raise
dust in endemic regions [68]. An outbreak of sympto-
matic coccidioidomycosis was reported in 10 of 18
workers (56%) at an archeological site in Northeastern
Utah [69]. This represents the first occurrence of
Coccidioides infection of humans in this part of North
America. Sporadic cases of coccidioidomycosis are
regularly reported in regions where the disease is not
endemic (e.g., New York) [70]. Acquisition of the
disease in these cases is almost always confirmed to
be travel-related [68,71/73].
The most dramatic increase in the number of
reported cases of coccidioidomycosis has occurred in
Arizona [74/76]. During 1997, laboratory reporting of
coccidioidal infections became mandatory in Arizona,
after which a significant increase in the number of cases
was noted. In 2001, a total of 2,203 cases were reported
(rate of 43 per 100,000 population), compared to 1,551
cases in 1998 (rate of 33). Persons aged ]/65 years and
individuals with HIV infection had the highest inci-
dence, although symptomatic infections in all age
groups increased [76]. Coccidioidomycosis is now a
nationally reportable disease at the southwest regional
level through the National Electronic Telecommunica-
tion System for Surveillance (NETSS). A case defini-
tion that required laboratory confirmation of
coccidioidal infection was adopted. The laboratory
criteria for diagnosis are cultural, histopathologic, or
molecular evidence of the presence of Coccidioides
spp.; a positive serologic test for coccidioidal antibodies
in serum or cerebrospinal fluid based on 1) detection of
coccidioidal IgM by immunodiffusion, enzyme immu-
noassay (EIA), latex agglutination, or tube precipitin
reaction, or 2) detection of a rising titer of IgM or
complement fixation (CF) antibody (IgG) by immuno-
diffusion, EIA or the CF test. Positive laboratory tests
combined with coccidioidal skin test conversion from
negative to positive after onset of clinical signs and
symptoms [75] support the diagnosis of coccidioidal
infection.
Galgiani [15] has pointed out that, although exten-
sive epidemiological studies of coccidioidal infections
were performed in the U.S. during the 1940s and 50s
[77,78], nearly a half-century later Coccidioides has
been rediscovered as an emerging pathogen [79].
Several factors have contributed to the current high
profile of this endemic disease. As previously men-
tioned, a continuing increase of the resident population
in the Southwestern U.S. and the rising number of
visitors to the ‘Sunbelt’ has substantially elevated the
risk of human infection. Arizona is the third fastest
growing state in the U.S. and attracts large numbers of
elderly citizens, particularly from the northern region
of the country. In almost all cases, these individuals
have not been previously exposed to the pathogen, and
are at high risk of contracting symptomatic coccidioi-
domycosis. The increased incidence of immunocom-
promised persons in communities at large, including
patients with AIDS and cancer, and individuals who
undergo organ transplantation, has created an ex-
panded host population for this opportunistic fungus.
The endemic regions of coccidioidomycosis in the U.S.
include several major military installations, and recent
studies have emphasized the significance of Cocci-
dioides as a threat to military personnel who train in
southwest desert areas [80]. A study conducted on
1,438 troops stationed at a military site in Southern
California showed that the skin test conversion rate
from negative to positive reactivity with Coccidioides
antigen was 25.4% over a six-to-eight month period
after new recruits arrived on the base [81]. The results
of this study exemplify what can happen even when a
young, presumably immunocompetent but naı̈ve popu-
lation moves into an endemic area. The fact that this
fungus is a primary pathogen is well documented by a
report of coccidioidal infection in 10 of 22 members of
a deployment of Navy Seals on military maneuvers in
the San Joaquin Valley. All case patients were sympto-
matic, and 50% had abnormal chest radiographs [82].
The high virulence of Coccidioides, ease of infection
by inhalation of dry, air-dispersed spores, and biogeo-
graphic range in heavily populated regions of North
America (including military bases) has raised fears of
the biohazardous nature and bioweaponizing potential
of this human pathogen [83]. It has been argued,
however, that Coccidioides is an unlikely choice as a
biological weapon [84]. Nevertheless, the Centers for
Disease Control now mandate that research involving
live cultures of the infectious phase of Coccidioides be
– 2004 ISHAM, Medical Mycology, 42, 189/216
A vaccine against coccidioidomycosis 193
conducted under the containment conditions of a
biological safety level 3 (BSL3) laboratory. Coccidioides
spp. is the only fungal pathogen on the ‘select agent’
list, which includes viruses, bacteria and toxins con-
sidered to be potential bioweapons (www.nih.gov/od/
ors/ds/pubs/appendxa.html). Research involving these
agents is currently regulated under the US Public
Health Security and Bioterrorism Preparedness and
Response Act of 2002.
In January 2003, a National Institute of Allergy and
Infectious Disease (NIAID)-appointed Blue Ribbon
Panel examined various issues related to ‘‘Biodefense
and Its Implications for Biomedical Research’’
and published its recommendations for the revised
NIAID categories B and C Priority Pathogen
Lists (www.niaid.nih.gov/biodefense/research/category-
bandc.pdf). It was recommended that Coccidioides be
added to the category B list, which would mean that
investigators working with this pathogen would be
eligible for biodefense research funds that are currently
available for studies of other microbes on the A, B, and
C lists. At present, however, investigations of Cocci-
dioides and coccidioidomycosis remain ineligible for
these research funds, even though scientists working
with the pathogen are subject to the same time-
consuming and costly regulations as those investigating
select agents that do qualify for biodefense research
grants. We have argued that Coccidioides should be
either added to the NIAID category ‘B’ or ‘C’ list of
priority pathogens, or deleted from the lists of select
agents.
Protection against coccidioidomycosis is
feasible
A compelling argument for the feasibility of a vaccine
against coccidioidomycosis is that natural, human
infection with Coccidioides results in lifelong immunity
to the organism [1,85]. Several early studies of experi-
mental coccidioidomycosis in animal models showed
that immunization with an attenuated strain of the
pathogen protected against a lethal, intranasal infec-
tion of the host [86,87]. The mouse is the most
extensively used animal model for studies of coccidioi-
dal infection [88], and differences in susceptibility to
disease have been observed between murine strains
(BALB/c/C57BL/6/DBA/2) [89]. BALB/c mice are
the most susceptible to disseminated coccidioidomyco-
sis following intranasal challenge with arthroconidia,
and this strain has been used as a stringent test of the
protective efficacy of experimental vaccination proto-
cols. Although immunization of BALB/c mice with the
original attenuated strains of Coccidioides prolonged
the survival of the animals against a lethal challenge,
both the vaccinating organism and pathogen appar-
ently persisted in the host. In addition, avirulence
proved to be an unstable condition in these early
experiments, which led to the abandonment of live
vaccines against the disease [85]. However, live attenu-
ated vaccines against other infectious diseases, such as
the Bacille Calmette-Guérin (BCG) vaccine against
tuberculosis, have revealed some degree of success and
are still widely used [90/92]. With the advent of
recombinant DNA technology, attenuated strains of
microbial pathogens have been generated by specific
gene deletion strategies, and this has provided both a
clear understanding of the mechanism by which
pathogenicity is inactivated, and confidence that the
mutated strain will not revert to the virulent form. A
mutant strain of C. posadasii which has been shown to
be avirulent in mice was generated in our laboratory by
the deletion of a single chitin synthase gene (CHS5 )
[93]. The null mutant (Dchs5 ) showed atypical mor-
phology and retarded growth in vitro, and failed to
develop into the parasitic phase in vivo. BALB/c mice
were immunized subcutaneously with the live Dchs5
strain together with incomplete Freund’s adjuvant
(IFA), and then challenged intranasally with a lethal
inoculum of arthroconidia derived from the parental
strain of C. posadasii . The adjuvant was included
during the vaccination protocol to help generate a
depot of immunogen. However, replacement of IFA
with PBS had no apparent effect on protective im-
munity. All immunized animals survived beyond 45
days post-challenge, compared to none of the control
mice (Fig. 2). In addition, 11 of the 12 Dchs5 -
immunized survivors showed clearance of viable fungal
elements (including the vaccination strain) from the
lungs, liver and spleen. The U.S. Department of Health
and Human Services designated the genetically engi-
neered Dchs5 isolate of C. posadasii as an avirulent
strain of a select agent. This avirulent strain does not
pose a threat to public health and safety and can be
used for the development of diagnostics, vaccines,
and therapeutics (www.cdc.gov/od/sap/exclusion.htm).
Although it is unlikely that a genetically engineered,
avirulent strain of Coccidioides would be acceptable as
a human vaccine, these results demonstrate the possi-
bility of potent and durable protection against
coccidioidal infection in a highly susceptible, immuno-
competent host. The results of this study also demon-
strate that host exposure to saprobic phase antigens
stimulates immune responses that protect against the
parasitic phase of the fungus. Spherules and endo-
spores are the dominant morphotypes in infected
tissue. However, it would seem that common protective
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antigens are expressed by hyphal elements and parasitic
cells.
An experimental, formalin-killed spherule (FKS)
vaccine has also been shown to protect mice against
disseminated coccidioidal infection, indicating that a
non-viable immunization strategy is feasible [94].
Between 1980 and 1985, a double-blinded human trial
was conducted using the FKS vaccine versus a placebo
[95]. The study involved almost 3000 volunteers, but
only a minority of the vaccinated individuals became
skin test-positive to Coccidioides. There was no differ-
ence in the number of cases of coccidioidomycosis or
the severity of disease in the FKS-vaccinated group
compared to the placebo group. One possible explana-
tion for the ineffectiveness of this vaccine is that
relatively small numbers of killed, parasitic cells could
be injected into humans without unacceptable local side
effects of pain and swelling. In vitro studies with FKS
were performed on human peripheral blood mono-
nuclear cells (PBMCs) obtained from skin test-positive
and -negative volunteers. The PBMCs from both donor
groups produced elevated levels of inflammatory cyto-
kines upon exposure to FKS, which could account for
the discomfort generated by vaccine in humans [2].
BALB/c mice immunized subcutaneously with the FKS
vaccine typically survive a lethal, intranasal challenge
of Coccidioides, but fail to clear the pathogen from
their lungs. A similar observation was made in BALB/c
mice immunized with the formalin-killed Dchs5 strain
(Fig. 2). Although 40% of the immunized mice survived
beyond 45 days post-challenge, all of these animals
showed persistent (chronic) infection in their lungs.
Investigations of the profile of immune response of
BALB/c mice immunized with the live Dchs5 vaccine
and then challenged with Coccidioides by the intranasal
route, will help to provide an understanding of the
factors that contribute to protective immunity against
coccidioidal infection. These studies are fundamental
to the development of an effective coccidioidomycosis
vaccine. However, the use of viable or non-viable,
undefined, multicomponent immunogens as vaccines
is problematic, not only because of potential toxicity
issues, but because compositional changes in different
preparations of the immunizing reagents could induce
significant variations in host immunoreactivity. Current
efforts to develop a vaccine against coccidioidomycosis,
therefore, have focused on the identification of purified
antigens which elicit a protective immune response.
Th1/Th2 pathways of immune response to
coccidioidal infection
Both clinical and experimental evidence have demon-
strated that T-cell immunity is pivotal for defense
against coccidioidomycosis [96]. Two functionally dis-
tinct subsets of CD4 T cells have been identified and
are distinguished by different patterns of secreted
cytokines [97]; T helper 1 (Th1) lymphocytes are
characterized by production of interleukin-2 (IL-2),
IL-12, tumor necrosis factor (TNF)-a, and gamma
interferon (IFN-g), while T helper 2 (Th2) cells produce
IL-4, IL-5, IL-6, and IL-10. Cytokines play a major
role in the activation of the Th1 and Th2 pathways of
immune response, and many of the T-cell receptors and
signal transduction events associated with Th1/Th2 cell
differentiation have been characterized [98]. These two
cytokine profiles correlate with resistance and suscept-
ibility to Coccidioides infection, respectively [96,99/
101]. Th1 cells secrete cytokines that initiate and
participate in cell-mediated immune responses, includ-
ing the activation of macrophages, while the Th2 subset
of T lymphocytes secrete cytokines that stimulate B-
cells to produce antibodies, activate mast cells and
eosinophils, and may down-regulate cellular immune
responses [102]. Th2 immunodominance compromises
host protection against coccidioidal infection and
exacerbates the course of disease [103]. Huffnagle and
Deepe [104] have pointed out that host response to
Fig. 2 BALB/c mice immunized with a live, avirulent strain of C.
posadasii (k; Dchs5 ) showed 100% protection against a lethal
challenge of the parental strain (C735). Survival plots of BALB/c
mice immunized with the formalin-killed Dchs5 (%) or the formalin-
killed wild type (wt) strain (\) and challenged by the same route are
compared to the survival of non-immunized mice (m). In each case,
female mice (18/20 gm; 12 per group) were immunized subcuta-
neously with hyphal fragments (250/750 colony-forming units
[CFUs] suspended in 100 ml of 50% [v/v] IFA in PBS). Immunization
was performed twice, two weeks apart, using the same immunogen.
The mice were challenged with 100 viable arthroconidia by the
intranasal route 4 weeks after the second immunization (boost). In a
separate experiment (results not shown), immunization with the live,
avirulent Dchs5 stain was performed as above but in the absence of
IFA. All mice survived beyond 45 days post-challenge, and the
pathogen was cleared from their lungs, liver, and spleen.
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systemic fungal infections ‘‘is the outcome of an
interplay between innate immunity, adaptive immunity
(Th1, Th2, T regulatory cells, B cells and antibodies)
and fungal virulence factors.’’
Alveolar macrophages are most likely among the
first innate cells to encounter and engulf arthroconidia
of Coccidioides, but in vitro studies have suggested that
the majority of these fungal cells survive [21,105]. The
ability of the arthroconidium to withstand the attack of
macrophages has been suggested to be at least partly
due to the impermeable nature of its outer conidial wall
layer, which is rich in hydrophobins [106]. The latter are
cysteine-rich proteins that typically occur as linear,
crystalline structures (rodlets) at the surface of air-
dispersed conidia produced by most filamentous fungi.
A mutant strain of Aspergillus fumigatus which lacks
rodlets has been shown to be more sensitive to killing
by alveolar macrophages than the parental strain [107].
Arthroconidia of Coccidioides germinate in vivo by
undergoing isotropic growth and differentiation into
large, multinucleate spherules, approx. 40/100 mm in
diameter. At this stage, the parasitic cells are too large
to be engulfed by host phagocytes. Each spherule
subsequently endosporulates to produce ]/200 endo-
spores (see Fig. 1). Amongst the medically important
fungi, this high reproductive capacity in vivo is a
feature which is peculiar to Coccidioides, and undoubt-
edly contributes to its ability to infect and colonize the
host.
The size of the inhaled arthroconidial inoculum and
intrinsic factors that govern the immune status of the
host [108] are pivotal in determining the outcome of
disease. To exemplify this point, BALB/c and C57BL/6
mice were first immunized with a recombinant, proline-
rich antigen (Ag2/Pra), one of the vaccine candidates
currently under investigation [109]. The mice were then
challenged intranasally with different amounts of
arthroconidia. Protection in vaccinated BALB/c mice
was lost when more than seven arthroconidia were used
for intranasal inoculation, while vaccinated C57BL/6
mice were still protected when challenged with a 20-
fold-larger number of spores [56]. A contributing factor
to this difference in susceptibility is that naı̈ve C57BL/6
mice develop a predominant Th1 response to infection,
while BALB/c mice mount a major Th2 response.
Dendritic cells (DCs) are key players in the host innate
cell repertoire, and may influence this difference in
immune response between the two inbred strains of
mice. DCs are one of the earliest cell types to be
exposed to the pathogen, are the most potent antigen-
presenting cells (APCs), and have the ability to activate
lymphocyte response against the microbial infection
[110]. Coccidioides antigens have been shown to
activate immature DCs in vitro to become mature
DCs [111]. The latter are characterized by increased
expression of major histocompatibility complex II
(MHC class II) molecules at the cell surface, produc-
tion of Th1-type cytokines, up-regulation of costimu-
latory molecules, and increased ability to activate T
cells through Toll-like receptors (TLRs) [104]. DC and
other host cell recognition of various microbial mole-
cules is mediated by binding of pathogen-derived
ligands to specific surface-expressed TLRs (currently
10 functionally distinct TLRs have been reported)
[112]. Naı̈ve splenic DCs from BALB/c mice have
been shown to express elevated levels of TLR2, -4, -5,
and -6 mRNA, while DCs from C57BL/6 mice
preferentially express TLR9 [110]. When exposed to
known TLR ligands from Listeria monocytogenes, DCs
from BALB/c mice responded by production of large
amounts of the chemokine, monocyte chemoattractant
protein 1 (MCP-1), while DCs from C57BL/6 mice
produced significantly higher levels of IL-12p40. MCP-
1 has been reported to enhance Th2 differentiation in
vitro and the Th2 pathway of immune response in vivo
[113]. As indicated, the latter may contribute signifi-
cantly to the susceptibility of BALB/c mice to dis-
seminated coccidioidomycosis. Understanding the
differences in basal expression of TLRs in BALB/c
and C57BL/6 mice, as well as the specific roles of TLRs
in innate antifungal response [114], may provide in-
sights into the factors that contribute to differences in
susceptibility to coccidioidomycosis within the human
population.
The histopathology of disseminated coccidioidal
infections in humans and mice shows similar features
[103]. For example, both infected human and murine
lung tissue reveal comparable interactions of host cells
with Coccidioides spherules prior to and after endo-
spore release [115] (Fig. 3A and B, respectively). At the
pre-endosporulation stage, spherules are frequently
found in association with damaged lung tissue (Fig.
3A). Recent evidence has been presented that damaged
host cells release uric acid that forms crystals capable of
activating dendritic cells [116]. The DCs, in turn, signal
inflammatory cells and T lymphocytes to respond to
the insult. This may be a second mechanism, in
addition to microbial ligand-TLR interactions, for the
host immune system to scan for signs of danger and
strangers [117]. Prior to endospore release, the spherule
outer wall (SOW) layer has been shown to be composed
of a lipid/glycolipid/glycoprotein matrix [118/121].
This observation is in agreement with that of Target
and Breslau [122], who first reported that the walls of
spherules are rich in ‘‘lipid complexes.’’ The potential
significance of this SOW layer is that its lipid compo-
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nents may be processed by specialized CD1-reactive T
cells and presented as lipid antigens to lymphocytes
with diverse T cell receptors (TCRs) [123,124]. It is now
well established that CD1d molecules in mice present
microbial-derived lipid antigens to T cells, suggesting
that they participate in host defense against pathogens.
The major population of CD1d-restricted T lympho-
cytes has been identified as Va14 natural killer T
cells, which apparently can function as APCs and have
been shown to play a key role in the innate phase of
host protection against microbial pathogens [125,126].
CD1d-reactive natural killer T (NKT) cells can pro-
duce Th1- and/or Th2-type cytokines and activate IL-
12 production in response to initial microbial infection.
NKT cells respond to early immune signals, augment
APC IL-12 production, activate NK cells, and are
implicated in the regulation of adaptive immune
responses [127]. Mice which lack the CD1d receptor
molecule (CD1d/) were evaluated for their suscept-
ibility to the Lyme disease spirochete, Borrelia burg-
dorferi . The latter is an extracellular pathogen that
expresses proinflammatory lipid antigens at its cell
surface [128]. The CD1 knock-out mice exhibited
impaired resistance to the spirochete pathogen. The
possibility that CD1 may function as antigen-present-
ing molecules that bind and present lipid antigens of
SOW during early stages of coccidioidal infection is
worthy of exploration.
Isotropic growth of endospores within the maternal
spherule results in pressure applied to the inner
circumference of the spherule wall, which eventually
causes it to rupture. As the contents of the endospor-
ulating spherule are released, the host mounts an
intense inflammatory response. Neutrophils are the
dominant innate cells found at sites of endospore
release (Fig. 3B) and most likely secrete both IL-12
and IL-10, a characteristic early response to fungal
infections [129]. In fact, IL-12 is produced by a variety
of APCs, including dendritic cells and macrophages.
Co-administration of an IL-12 expressing plasmid to
BALB/c mice, together with a cDNA vaccine encoding
the Ag2/Pra antigen described above, has been shown
to enhance the vaccine-induced protective immunity
against experimental coccidioidomycosis by stimula-
tion of Th1-associated immune responses [130]. IL-12
has a multiplicity of functions, which include the
stimulation of T lymphocyte and natural killer cell
proliferation, increased cytolytic activity of macro-
phages, and induction of secretion of Th1-type cyto-
kines such as IL-2, TNF-a, and IFN-g [99,131]. The
relative amounts of IL-12 and IL-10 secreted in murine
lung tissue during early stages of coccidioidal infection
may significantly influence the outcome of disease.
Although IL-10 production is important in regulating
the synthesis and secretion of IL-12 by host innate cells
[132], a persistent, elevated level of IL-10 may con-
tribute to increased host susceptibility to disseminated
coccidioidomycosis. Coccidioides -infected BALB/c
mice produce more IL-10 and IL-4 during early stages
of disease than inbred strains with higher resistance to
infection (e.g., C57BL/6 and DBA/2) [133]. Cocci-
dioides -infected, IL-10-deficient mice are as resistant
to coccidioidomycosis as DBA/2 mice, suggesting that
a persistent, high level of IL-10 production during
coccidioidal infection has a net compromising effect on
host immune response. The ability of IL-10 to suppress
accessory cell functions required for optimal T-cell
activation makes it a ‘down-regulator’ of cell-mediated
immunity [134].
Little is known about the involvement of NK cells in
host immune response to Coccidioides infections.
Indirect evidence has suggested that NK cell compo-
nents of human peripheral blood lymphocyte prepara-
tions inhibit growth of endospores in vitro, and that
Fig. 3 Paraffin-sections of infected murine
lung tissue, which show spherules of C.
posadasii prior to and after endospore release
(A and B, respectively). Note the intense host
inflammatory cell response to the ruptured
spherule (primarily polymorphonuclear neu-
trophils [PMNs]) (B). The bar in (A) repre-
sents 60 mm.
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this inhibitory effect can be enhanced by the addition
of IFN-g [135]. As indicated above in the discussion of
the function of CD1d-restricted NKT cells, NK cells in
general seem to play an important role in innate
immunity against infectious diseases and in linkage to
adaptive immunity [136]. Two subsets of human NK
cells have been distinguished on the basis of their
relative expression of CD56; CD56dim cells comprise
the majority of NK cells that function as effectors of
natural cytotoxicity and antibody-dependent cellular
cytotoxicity, while CD56bright cells have immunomo-
dulatory properties that function through secretion of
cytokines, including IFN-g [137]. Activated NK cells
have also been shown to prime DCs to produce IL-12
[138], which is necessary for IFN-g secretion by T
lymphocytes and the elaboration of a Th1 response
[104]. During the active phase of experimental
Histoplasma capsulatum infection in C57BL/5 mice
(B/3 weeks post-challenge), macrophages and NK cell
numbers sharply increased during the initial inflamma-
tory response, followed by a rise in the CD4 T cell
population [139]. The first cytokine transcripts to be
detected in these infected mice were for IL-12 and IL-4,
followed by IFN-g. The authors showed that quantita-
tively, the increase in the IFN-g transcript level was 2
logs higher than the transcript levels of IL-12 and IL-4
at about 3 weeks post-challenge. Similar observations
have been made in resistant strains of mice infected
with Coccidioides [96,99,101]. On days 9 to 10 post-
infection with H. capsulatum , following the initial
inflammatory response, the hierarchy of IFN-g expres-
sion was CD4/CD8/NK cells. These observa-
tions support the contention that cytokine secretion by
NK cells plays an important supporting role in
immunomodulation during early stages of infection.
Production of interleukin-4, -5, and -6 significantly
influences the outcome of coccidioidomycosis. A per-
sistent high level of IL-4 production in lungs of naı̈ve
BALB/c mice during stages of Coccidioides infection
appears to down-regulate CMI. T helper cells are a
major source of IL-4, although mast cells can also
secrete this cytokine [113,132]. IL-4 knock-out mice
have been shown to be more resistant to A. fumigatus,
and shift from a Th2-type response to a Th1 response
to infection [140,141]. Neutralization of endogenous
IL-4 in Coccidioides -infected BALB/c mice by admin-
istration of neutralizing anti-IL-4 antibody led to a
significant reduction of fungal burden in their lungs
[101]. Persistently high levels of IL-5 and IL-6 have
been observed in BALFs of non-immunized BALB/c
and C57BL/6 mice between day 4 post-infection with
Coccidioides and death of the animals (Fig. 4A, B).
Eosinophilia is an indicator of coccidioidal infection,
and is noted in approximately 25% of patients diag-
nosed with this fungal infection [103]. In fact, marked
eosinophilia may be an important clue that dissemina-
tion of Coccidioides has occurred [142]. IL-5 is an
eosinophil differentiation factor, and increased levels of
IL-5 in bone marrow correlate with the appearance of
increased eosinophil numbers in the blood of patients
[143]. Extensive clinical evidence has suggested that
eosinophils play an important role in the pathogenesis
of asthma, which is characterized by Th2 immunodo-
minance [144]. The key role of IL-5 in eosinophil
production and function has made this cytokine a
prime therapeutic target [145]. The use of IL-5 neu-
tralizing antibodies in animal models of asthma has
been shown to result in suppression of eosinophil
recruitment to the lungs [146]. However, the effects of
eosinophil recruitment to sites of inflammation may
not be entirely negative. Eosinophils produce growth
factors, and may play an important role in the
resolution of inflammation and tissue repair. Thus,
the effects of using antibodies raised against IL-5 to
reduce eosinophilia, particularly in humans, requires
careful study [145]. Nevertheless, IL-5 has been im-
Fig. 4 Profiles of cytokine response of non-immunized C57BL/6
mice to intranasal challenge with C. posadasii , as determined by
ELISAs of BALFs. (A) IL-5; (B) IL-6. Data were derived from 3 mice
per time point. Mice were challenged with 80 arthroconidia. Similar
profiles of cytokine response were observed in non-immunized,
Coccidioides -infected BALB/c mice (not shown).
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plicated in the recruitment and activation of eosino-
phils within the lungs of the Coccidioides- infected host,
resulting in localized tissue damage. Huffnagle and
coworkers [147] have shown that development of
chronic eosinophilia in the lungs of Cryptococcus
neoformans-infected C57BL/6 mice is a non-protective
immune response that causes significant lung pathol-
ogy. In murine coccidioidomycosis, a persistently high
level of IL-5 production is indicative of a dominant Th2
response to infection, and a poor prognosis of disease
outcome. IL-6 is considered a pleiotropic cytokine
[148]; it has been described as both a pro-inflammatory
and anti-inflammatory molecule. Early IL-6 expression
plays a pivotal role in the induction of host inflamma-
tory response to infection. However, persistent antigen-
driven, APC-derived IL-6 production can influence
CD4 T cells to produce IL-4 and, thereby, promote
Th2 differentiation and inhibit Th1 polarization. The
latter has been suggested to occur by up-regulation of
suppressor of cytokine signaling (SOCS ) gene expres-
sion, which interferes with IFN-g signaling and the
development of Th1 cells [149]. IL-6 secreted by
Mycobacterium tuberculosis -infected macrophages has
been shown to inhibit the activation responses of
uninfected macrophages to IFN-g, which contributes
to the inability of the cellular immune response to
eradicate infection [150]. We have shown that an inverse
relationship exists between the production of IL-6 and
IFN-g during progressive stages of coccidioidal infec-
tion in naı̈ve mice, as measured by cytokine enzyme-
linked immunosorbent assays (ELISAs) of BALFs over
a 2-week period post-infection (Fig. 4B). This time
course of reduction of IFN-g expression in the lungs of
infected mice correlates with dissemination of the
pathogen.
Recent evidence has suggested that persistently
elevated production of IL-6 may contribute to the
inability of regulatory T cells to control the activation
of T effector cells in response to the presence of the
pathogen [151]. This, in turn, could lead to intense
inflammation at sites of infection together with host
tissue damage, and further exacerbation of disease.
Interest in the function of regulatory T cells (TR) in
infectious disease is based on the current assumption
that they play an essential role in prevention of harmful
immune pathology during the course of microbial
infection [152]. Most members of this small subset of
CD4 T lymphocytes present in healthy individuals
(approx. 5 to 10%) are distinguished by their expression
of the activation marker CD25. However, it was the
discovery that the transcription factor FOXp3 acts as
the ‘master control gene’ for TR cells, which defined
this subset of lymphocytes as a distinct cell lineage
[153]. These naturally occurring, thymus-derived TR
cells (CD4CD25) have the ability to inhibit the
proliferation of T effector lymphocytes (CD4CD25)
by their secretion of cytokines (e.g., IL-10), and remain
functionally stable for long periods in the absence of
antigen [154]. Typically, the roles of CD4CD25 T
cells are to support the mobilization of T cell-mediated
immune response against an invasive microbe, while
simultaneously minimizing host tissue damage due to
immune pathology. The activities of T regulatory cells
during the course of infectious disease can also be a
potential liability. For example, recent studies of murine
infections with the malaria parasite Plasmodium yoelii
have indicated that activation of TR cells contributes to
immune suppression and helps the parasite to escape
from host immune responses [155]. Antibody depletion
of CD4CD25 TR cells protected mice from death
when infected with a lethal strain of P. yoelii. During
cutaneous infection of C57BL/6 mice with Leishmania
major, CD4CD25 T cells have been shown to
accumulate in the dermis where they suppress / by
both IL-10-dependent and IL-10 independent mechan-
isms / the ability of CD4CD25 effector T cells to
eliminate the parasite [156]. Depletion of
CD4CD25 T cells led to clearance of the pathogen.
However, the sterilizing immunity achieved under these
conditions resulted in loss of immunity to reinfection,
suggesting that an equilibrium is established between
regulatory and effector T cells at sites of chronic
Leishmania infection, which might reflect both parasite
and host survival strategies. A similar scenario may
exist during chronic infections with Coccidioides. A
molecular signaling complex which appears to regulate
the activities of CD4CD25 cells has been partially
defined [154]. This discovery gives credence to the
concept of ‘contrasuppression’ [157], which may be a
particularly important factor in the development of
protective immunity against Coccidioides infection.
Histopathological evidence suggests that host tissue
damage occurs at sites of coccidioidal infection where
the pathogen persists and high levels of IL-6 produc-
tion are maintained. The concept that host response
contributes significantly to pathogen-mediated damage
of host tissue has been well articulated by Casadevall
and Pirofski [158,159]. An intriguing proposal in this
commentary is that regulation of immune response and
generation of long-lasting protection against fungal
infections may, paradoxically, require the production of
both Th1 and Th2 cytokines to achieve a modicum of
Th1/Th2 balance [160]. Opsonizing antibodies which
bind to fungal pathogens have been suggested to
significantly influence both the nature of innate cell-
microbe interactions, as well as the development of
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long-lasting antifungal immunity [161]. This concept is
in opposition to current opinion of the importance of
antibody in protection against coccidioidal infection.
Antibody-mediated immunity (AMI) has always been
thought to be of little benefit since high antibody titers
in patients with coccidioidomycosis typically correlate
with poor clinical outcome [78]. However, antibody and
complement undoubtedly provide opsonic activity, and
enhance ingestion of the pathogen by host phagocytes.
Complement activation leads to release of molecular
fragments that are chemotactic for PMNs [162] (see
Fig. 3B), and opsonize arthroconidia and endospores
for engulfment by phagocytic cells. Nevertheless, no
evidence has been provided to date that a subset of
antibodies to specific Coccidioides antigens is protec-
tive [103]. However, this conclusion is based primarily
on clinical studies rather than extensive experimental
evidence. Casadevall [163] has provided a thoughtful
argument that the interactions of AMI and CMI
influence the outcome of fungal infections, and should
be viewed in the context of an integrated immune
response [164].
Considerably more is known about cytokine regula-
tion of Th1 and Th2 responses than the roles of
chemokines in host response to fungal infections in
general, and coccidioidomycosis in particular. Chemo-
kines are small, mainly soluble cytokines that are
chemotactic for leukocytes [165]. Since their discovery
in the early 1980s, the number of chemokines has risen
to almost 50 [166, http://cytokine.medic.kumamo-
to.u.ac.jp]. Members of the chemokine family fall
mostly into two groups; the CC chemokines with two
adjacent cysteines near the N-terminus, and CXC
chemokines in which the equivalent two cysteine
residues are separated by another amino acid [132].
These two groups of chemokines act on different sets of
receptors. The CC chemokines bind to CC chemokine
receptors (CCR1, CCR2, etc.), while CXC chemokines
bind to CXC receptors (CXCR1, CXCR2, etc.). More
than 20 chemokine receptors have been identified.
Although it first appeared that the chemokine network
incorporates a high degree of redundancy, results of
murine gene-targeted chemokine and chemokine re-
ceptor knock-out studies have suggested that chemo-
kine regulation is incredibly intricate [165,167]. Several
chemokines/chemokine receptors have been the focus
of attention in fungal infections because of their
influence on chemotaxis of host innate immune cells,
as well as Th1 vs Th2 polarization of immune response
to the microbial insult. For example, Eotaxin-a is a
chemokine that functions cooperatively with IL-5 in
the recruitment of eosinophils to sites of inflammation
[145]. During early stages of T cell activation, post-
infection, naı̈ve T cells in secondary lymphoid tissue
express C-C chemokine receptor 7 (CCR7), which is a
major chemotactic receptor for dendritic cells [168].
Activated T cells express CCR2, which may be involved
in blood-to-lung migration of antigen-presenting cells,
such as DCs and macrophages [169,170]. Polarized Th1
and Th2 cells are distinguished by their expression of
high levels of CXCR3 or CXCR4, respectively [171].
CXCR3 is a major chemotactic receptor for activated
Th1 T cells, while CXCR4 is a chemoattractant for Th2
cells. Traynor et al. [167] have reported that CCR2 is
required for Th1 polarization in murine lungs infected
with Cryptococcus. Based upon results of our early
studies (unpublished), we suspect that expression of
MIP-1a and CXCR3 (Th1-related), and MCP-1 and
CXCR4 (Th2-related) play pivotal roles in trafficking
of APCs and T cells during early stages of coccidioidal
infection. Current studies of chemokine and chemokine
receptor expression in mice at sites of lung infection
with Coccidioides are ongoing in our laboratory. The
techniques employed in these investigations are illu-
strated and discussed below under the section on
measurements of host protection.
A summary of the major factors known to contribute
to host immune defense against Coccidioides infection
is illustrated in Fig. 5. The pathogen and host establish
both an intracellular and extracellular relationship.
Arthroconidia and endospores are phagocytosed, but
the latter appear to be the most vulnerable to growth
inhibition and killing by activated phagocytes. The
response of CD4 T lymphocytes to infection has been
assumed to be essential for protection against cocci-
dioidomycosis, while the role of CD8 T cells in this
process is unclear [103]. Although cytotoxic T lympho-
cyte (CTL) activity in coccidioidomycosis has not been
reported, a role for CD8 T cells in host defense was
suggested in the report that optimal protection by
adoptive transfer of immune spleen cells to syngeneic
mice occurred when both CD4 and CD8 cells were
present [96]. Depletion of either subset reduced the
level of protection conferred to the recipient. CD8 T
cells are known to be activated in response to intracel-
lular pathogens, and share some of the same effector
mechanisms as CD4 T cells, including the secretion of
IFN-g [172]. It would seem logical, therefore, that
CD8 T cells may play a role in cell mediated
immunity under conditions of a reduced or absent
CD4 T cell population (e.g., in patients with AIDS).
Wüthrich et al. [173] demonstrated that mice depleted
of CD4 T cells can be protected by vaccination
against an extracellular or intracellular fungal patho-
gen, and the key players in this immune protection were
the antigen-activated memory CD8 T cells. The latter
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were activated in a MHC I-restricted manner and
secreted Th1-type cytokines to provide durable vaccine
immunity to the mice. These results suggest that a
therapeutic vaccine against systemic fungal infections
could be used to immunize patients with CD4 T cell
deficiencies. Identification of the key transcription
factors which regulate development of functionally
distinct T cell lineages is almost at hand [174], and
the results of these studies will contribute significantly
to our understanding of how CD4/CD8 T cell
responses to microbial infections are coordinated. At
this point, it is not known whether CD8 T cells can be
stimulated by a coccidioidal vaccine to provide protec-
tion to an immunodeficient host, or whether a ther-
apeutic vaccine against coccidioidomycosis in patients
with reduced CD4 T cell numbers is feasible.
Adjuvants
Adjuvants include naturally occurring and synthetic,
bioreactive products which are used for immune-
potentiating activity that is optimally suited to vaccines
developed against particular diseases. During the past
few years, several authoritative reviews have been
published on the discovery and delivery of vaccine
adjuvants [e.g., [175/177]]. It is fair to state that
‘‘adjuvant design has historically had a touch of
alchemy at its heart due to its reliance on the complex
biology of innate immune activation’’ [177]. On the
other hand, it is evident from the above discussion that
substantial progress is being made toward a mechan-
istic understanding of innate immunity. With the
discovery of the TLR family of receptors, many
pathogen products with known immune-potentiating
activity have been shown to activate innate immunity
via TLR binding and/or through their interaction with
an increasing number of non-TLR, innate cell-surface
expressed pattern-recognition receptors (PRRs) [177].
Some TLRs seem to be highly promiscuous (e.g., TLR2
and TLR4), and have been shown to participate in
response to numerous and diverse immune-potentiating
reagents. In fact, TLR2 and 4 apparently play a more
general role in the initiation and amplification of the
early immune response, whereas other TLR family
members have evolved more specialized functions [177].
For example, bacterial lipopolysaccharide (LPS) binds
to the glycosylphosphatidylinositol (GPI)-anchored
membrane protein CD14, and activates both TLR2
and TLR4 to induce an immune response [178,179].
Thus, CD14 functions as a PRR under these condi-
tions, but lacks an intracellular signaling domain and
requires the TLRs for transmission of the activating
signal into the cell [180]. Overexpression of a constitu-
tively active form of TLR4 in transgenic mice results in
a significant increase in innate cell sensitivity to LPS
both in vitro and in vivo [179]. Upon infection with
Salmonella typhimurium , these transgenic mice pro-
duced markedly elevated levels of Th2 cytokines. The
long-term adjuvant effect of LPS exposure revealed in
these studies was the development of an excessive
inflammatory response which was detrimental to the
host. On the other hand, a detoxified form of bacterial
LPS isolated from Salmonella minnesota has been
shown to be an effective vaccine adjuvant. The
Fig. 5 Diagrammatic summary of murine innate and
acquired immune response to Coccidioides infection. Ab,
antibodies; CCR2, CC-type chemokine receptor 2 which
interacts with MCP-1 (see below); Ct, complement com-
ponent; CXCR3, CXC-type chemokine receptor which
interacts with IP-10 (IFN-g inducible protein); DC, den-
dritic cell; EO, eosinophil; IFN-g, interferon-gamma; IL,
interleukin; M8, macrophage; MCP-1, macrophage che-
moattractant protein-1 (CC-type chemokine); MIP-1a,
macrophage inflammatory protein-1 alpha (CC-type che-
mokine); NK, natural killer cell; PMN, polymorphonuclear
neutropil; Th1/Th2, T helper 1/T helper 2 immune response
pathways,; TNF-a, tumor necrosis factor-alpha.
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compound, known as monophorsphoryl lipid A
(MPL†; mol. weight approx. 1718 daltons), has been
shown to have greater Th1 than Th2 stimulating
potential. MPL has been extensively evaluated as an
adjuvant in human vaccine trials for malaria, hepatitis
B, and allergy desensitization. It has been shown to be
well tolerated, and enhances the efficacy of the
vaccination protocol [181]. The benefits afforded by
MPL in vaccine formulations are attributed to its
immunostimulatory effects on the innate immune
system, presumably mediated through the activation
of both TLR2 and TLR4. MPL activation of APCs
results in enhanced phagocytosis and microbicidal
activities. The latter are the consequence of elevated
levels of production of Th1-type cytokines, including
IL-12, TNF-a and IFN-g [182].
MPL has been used as an adjuvant together with
recombinant Ag2/Pra to test the effectiveness of this
experimental vaccine against coccidioidomycosis [109].
MPL was substituted for complete and incomplete
Freund’s adjuvants, which are not approved for human
use, and alum (aluminum hydroxide) which elicits a
dominant Th2 pathway of immune response [183].
BALB/c mice immunized with rAg2/Pra/MPL
showed significantly better protection against Cocci-
dioides infection, and higher levels of IFN-g produc-
tion than mice immunized with the recombinant
protein alone [109]. As an alternative to MPL, IL-12
has been tested in combination with Ag2/Pra for its
ability to mount a protective Th1 response against
murine coccidioidomycosis [184]. Interleukin-12 is a
heterodimeric cytokine composed of a 40-kDa and 35-
kDa chain [184]. The antigen and cytokine (both
chains) were delivered to BALB/c mice intramuscularly
as cDNA constructs in a mammalian plasmid vector,
and resulted in enhanced protection against Cocci-
dioides compared to mice immunized with Ag2/Pra
cDNA alone. The protective response was character-
ized by increased IFN-g production and a high titer of
Th1-associated, anti-Ag2/Pra-specific IgG2a antibo-
dies. However, an approximately equal titer of Th2-
associated, antigen-specific IgG1 antibody was also
detected in mice that received both antigen and
adjuvant, and immunization with the combined antigen
plus adjuvant resulted in little reduction of the fungal
burden in lungs of mice challenged by the intranasal
(pulmonary) route compared to control animals. The
authors suggested that intranasal delivery of the
combined Ag2/Pra-IL-12 cDNA vaccine directly to
the lungs may improve its effectiveness. The results of
these studies have not yet been reported. A variation of
this vaccine formulation still untested against cocci-
dioidomycosis is the inclusion of the recombinant
antigen and IL-12 protein admixed with alum for
immunization by the conventional subcutaneous route.
Previous studies have demonstrated that coadsorption
of antigen and IL-12 to alum promotes both Th1-type
cytokine production and high levels of the correlated
(IgG2a) antibody response [185]. As indicated in the
earlier discussion of Th1/Th2 polarization of immune
responses to coccidioidomycosis, it is possible that both
cellular and humoral immunity are required for potent
and durable protection against coccidioidal infection.
The clinical application of IL-12 as a vaccine adjuvant,
however, has encountered several problems. The het-
erodimeric molecule is expensive, difficult to manufac-
ture, and its safety in human clinical trials is still
questionable [182].
Multiple recent studies have reported that synthetic
oligodeoxynucleotides (ODNs) with CpG motifs pro-
vide enhanced immune response to co-delivered anti-
gens [92,186/188]. Vaccine formulations that include
CpG oligodeoxynucleotides combined with recombi-
nant antigens of C. posadasii [189,190] and A. fumiga-
tus [186] have proved to promote Th1 response and
provide good protection against the respective mycoses.
A recent report, relevant to our use of the live, avirulent
vaccine of Coccidioides described above, showed that
CpG ODN improved the safety, potency and durability
of a live vaccine against cutaneous leishmaniasis [92].
CpG DNA binds to TLR9 [191] and is suggested to
directly activate dendritic cells and macrophages and
enhance production of cytokines that create a Th1-like
milieu in lymphoid tissue [192]. The Th1 response in
the presence of CpG includes elevated levels of IL-12,
IFN-g, TNF-a expression and production of anti-
microbial nitric oxide [92,193]. Co-administration of
CpG ODN with soluble protein antigens in incomplete
Freund’s adjuvant has been shown to promote Th1
responses in vitro [194] and in vivo against murine
coccidioidomycosis [189,190]. The sequence of the
immunostimulatory CpG ODN (5’ to 3’) used to
immunize mice was TCCATGACGTTCCTGACGTT
(CpG motifs are underlined). The synthesized products
contain a phosphorothioate backbone to ensure DNA
stability in vivo. CpG ODN has proven to be superior
to other well-tested adjuvants for its ability to induce
Th1-biased immune responses. A major advantage of
this DNA adjuvant is its apparent lack of toxicity in
primates, although repeated administration (7/20
days) of high amounts of CpG ODN to mice (60 mg/
dose) resulted in immunotoxicity and hepatoxicity
[195]. Nevertheless, results of early clinical studies of
CpG DNA have indicated that CpG ODN is tolerated
by humans, works well in the immature immune system
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of neonates, and is a strong mucosal adjuvant when
delivered intranasally [196].
Measurements of host protection
As previously pointed out, protection of coccidioido-
mycosis-susceptible BALB/c mice against a lethal
inoculum delivered via the intranasal (i.n.) route is
the most stringent evaluation of the effectiveness of a
candidate vaccine. For preliminary screens of the
efficacy of a vaccine protocol, we routinely challenge
immunized mice by the intraperitoneal (i.p.) route, and
then sacrifice the animals 12/14 days post-inoculation
to determine the fungal burden in their spleen and
lungs [189,190,197]. The pathogen apparently migrates
to the lungs from the site of i.p. inoculation, and
marked reduction in colony-forming units in this organ
has proved to be a good indicator of vaccine efficacy.
The i.p challenge mode provides more precise control
of the size of the inoculum actually delivered to the
host, and achieves better reproducibility of levels of
coccidioidal infection in the lungs than by the intrana-
sal route of inoculation. The results of a representative
study of fungal burden in the lungs and spleen of
immunized and non-immunized mice challenged via the
i.p. route versus the i.n. route are shown in Fig. 6. The
numbers of colony-forming units (CFUs) per lung are
expressed on a log scale. Because these values do not
fall into a normal distribution, the Mann-Whitney U
test was used to compare the median counts. Statistical
significance of survival differences between groups of
mice (at least 10 animals/group) were calculated by the
Kaplan-Meier method.
An unexpected observation in this evaluation of the
particular vaccine candidate was that the 1 mg dose of
the recombinant protein plus adjuvant (i.e., 1 mg
rGel1/CpG/IFA) elicited a more protective immune
response than the 5 mg dose [190]. This observation was
consistent in both the fungal burden and survival
studies (Fig. 6A/C). Although the difference in survi-
val using these two doses was not statistically signifi-
cant, the consistency of results in animals immunized
with 1 mg of rGel1 suggested that this vaccination dose
indeed provided superior protection than the higher
dose of recombinant protein. We further explored this
difference in immune response by examination of
cytokine production in these two groups of immunized
and challenged mice compared to the non-immune,
infected controls. The results suggested that immuniza-
tion with 1mg of rGel1 stimulated an early Th1 pathway
of immune response, indicated by higher levels of IL-12
(Fig. 6D) and IFN-g production, and an increased level
Fig. 6 Evaluations of fungal bur-
den in lungs (A) and spleen (B) of
BALB/c mice, and survival (C) of
C57BL/6 mice immunized with
recombinant Gel1 (either 1 mg or
5 mg per dose) plus adjuvant
(CpG/IFA) and challenged with
a lethal inoculum via either the
intraperitoneal route (A,B; 100
arthroconidia) or the intranasal
route (C; 80 arthroconidia).
Groups of 12 mice were used for
these two studies. Asterisks indi-
cate a significant difference be-
tween rGel1-immunized and non-
immunized mice (adjuvant or PBS
alone). (Fig. 6A/C reproduced
with permission from the Ameri-
can Society for Microbiology; ta-
ken from reference 190, Infect.
Immun). (D). Profiles of IL-12
production by rGel1-immunized
C57BL/6 mice (1 mg dose vs. 5 mg
dose) compared to non-immu-
nized mice, as determined by ELI-
SAs of BALFs (A/C). Three mice
per time point were assayed for
each immunization protocol.
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of rGel1-specific IgG2a titer when compared to in-
fected mice immunized with the 5 mg dose. In fact, the
latter group of mice appeared to respond to infection in
a Th2 manner, with elevated levels of IL-5 and IL-10
production and high titers of rGel1-specific IgG1
antibody. In the absence of data on the distribution
of Th1 and Th2 epitopes in rGel1, it is premature to
speculate about the reason for this difference in
immune T cell reactivity. However, the results of this
experiment illustrate the need to examine the profile of
cytokine expression as well as other indicators of a
protective vs. non-protective response in immunized
mice at different times post-challenge in order to
critically evaluate the potency and durability of the
candidate vaccine.
We have used two methods to examine the cytokine
profile and thereby evaluate the protective efficacy of a
candidate vaccine at selected times post-challenge: by
quantitative analysis of cytokine proteins in bronch-
oalveolar lavage fluid of immunized, infected mice, and
by quantitative analysis of cytokine gene expression in
isolated, cryosectioned lung tissue. As discussed above,
immunization with 1-mg vs. 5-mg doses of rGel1
induced different cytokine profiles in C57BL/6 mice
post-challenge. In Fig. 6D, we compared the amounts
of IL-12 detected in BALFs (as determined by ELISAs)
over a two-week period post-challenge in vaccinated
versus control mice. The sharp reduction in the amount
of IL-12 present in mice immunized with 5 mg of rGel1
between days 4 and 14 post-challenge contrasted with
the relatively high levels of this cytokine in mice
immunized with 1mg of rGel1. These results correlated
with differences in fungal burden (Fig. 6A,B) and
survival (Fig. 6C). A semi-quantitative, but less time-
consuming and more cost-effective method to initially
evaluate changes in cytokine profiles can be conducted
using commercially-available monoclonal/polyclonal
antibody arrays to capture selected proteins from the
BALF preparations [198,199]. The advantages of using
these protein arrays are that many cytokines can be
detected simultaneously using a membrane format, and
the sensitivity and detection range are comparable to
ELISA. We have found that the murine cytokine arrays
are valuable adjuncts to cytokine profile analyses, and
permit initial identification of individual cytokines in
BALF preparations which can then be more precisely
and critically examined by ELISAs.
The detection of cytokines in BALFs provides an
indication of the nature of the total immune response in
the lungs of i.n.-challenged mice, which for a particular
murine strain will vary depending on the amount of
original inoculum that reached the lungs and the degree
of the infection within the lobes of the lungs. As an
alternative to these assays, we have used laser capture
microdissection (LCM) combined with quantitative,
real time-PCR (QRT-PCR) to evaluate the local, in
situ amounts of specific cytokine mRNA in host cells
located adjacent to sites of coccidioidal infection in
freshly prepared cryosections of murine lung tissue
[200/202]. It is reasonable to assume that examinations
of cytokine expression levels in innate cells and
activated T lymphocytes adjacent to the pathogen in
tissue sections provide accurate evaluations of the
nature of localized host response to infection. The
LCM procedure in our laboratory is conducted using
an Arcturus PixCell IIe microscope equipped with an
infrared diode laser, as well as fluorescence and bright-
field illumination (Arcturus, Mountain View, CA).
Immunized or non-immune control mice infected with
Coccidioides are injected intravenously with 50 ml of a
fluorochrome (Blankophor, 1 mg/ml) 30 min prior to
sacrifice. The stain has been shown to reach the lungs
and bind specifically to the fungal cell wall [203].
Blankophor is nontoxic and has no recognized effects
on host immunity. Frozen sections of infected lung
tissue (approx. 8 mm thick) are obtained from vacci-
nated mice, fixed, and used as the source of total RNA
for subsequent studies. The advantage of in vivo
staining of Coccidioides cells is that it permits identi-
fication of infection sites in lung sections by fluores-
cence microscopy, and minimizes the washing steps and
loss of RNA prior to the microdissection and capture
procedures. The laser beam is used for separate
dissections of either the pathogen or the adjacent host
tissue (Fig. 7). The resolution of fluorescence micro-
scopy is adequate to distinguish between different
stages of the parasitic cycle (see Fig. 1). The laser-
dissected spherules or host tissues are captured by
contact with the surface of a patented film attached to
the cap of an Eppendorf microcentrifuge tube contain-
ing the reagents for RNA extraction. The total RNA is
reverse-transcribed and used as the template for QRT-
PCR assays of expression of either selected Cocci-
dioides genes or host cytokine genes (Fig. 8). LCM-
derived RNA has also been used to profile gene
expression by employing high density oligonucleotide
arrays [204]. This is a powerful method which can be
used to generate an unbiased survey of the host
transcriptome at sites of infection in lung tissue.
As previously indicated, ELISA determination of the
relative titers of vaccine antigen-specific IgG2a vs. IgG1
is also a valid predictor of a protective or non-
protective immune response against coccidioidal infec-
tion [109,189,190]. Comparative histopathology is like-
wise a valuable assay of the effectiveness of candidate
vaccines in stimulating the host to sequester and clear
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Fig. 7 Diagrammatic representation of metho-
dology used to obtain RNA from either C.
posadasii or host tissue isolated by laser capture
microdissection (LCM) from cryosections of in-
fected murine lungs.
Fig. 8 Examples of semi-quanti-
tative analysis of C. posadasii
gene expression and host cytokine
gene expression by reverse tran-
scription-PCR and quantitative,
real time-PCR (QRT-PCR). Tem-
plate RNA was obtained by LCM
from sites of infection in murine
lungs.
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the pathogen. The detection and characterization of
granulomas in infected lungs of mice (determination of
granuloma numbers, size and organization, presence/
absence of giant cells, and relative amount of collagen
using a collagen-specific dye) [205] may help to further
provide a meaningful evaluation of vaccine efficacy.
Vaccine candidates
As previously stated, current efforts to develop a
vaccine against coccidioidomycosis have focused on
the identification of purified antigens which elicit a
protective immune response. The majority of protective
antigens that have been characterized to date are
products of the parasitic phase of the fungus [103].
The most promising of these include two defined, cell
wall-associated antigens [56,190]. Early studies have
revealed that immunoprotective components of the
spherule wall could be isolated by alkali treatment
[206], or toluene extraction followed by deglycosylation
with hydrogen fluoride [207]. The Cox laboratory
cloned a protein that was present in the alkali-soluble,
water-soluble preparation of the spherule wall, and
referred to it as antigen 2 (Ag2) [208,209]. This
nomenclature was based on a reference system which
relies on two-dimensional immunoelectrophoretic se-
paration of crude preparations of saprobic and para-
sitic phase antigens designated coccidioidin and
spherulin [210]. The AG2 gene was reported to encode
a proline-rich protein with a predicted molecular mass
of 19.4 kDa. The deduced protein sequence contains 10
repeats (TXX’P), predicted signal peptide and C-
terminal GPI anchor, 8 cysteine residues, and 24
potential O -glycosylation sites. Simultaneous investiga-
tions of vaccine candidates in the Galgiani laboratory
identified a protective 33-kDa proline-rich antigen
(Pra) in SDS-PAGE gel separations of a hydrogen
fluoride-deglycosylated lysate of Coccidioides [211].
The PRA gene was cloned and shown to be identical
to the AG2 gene sequence. The difference in molecular
size of the predicted and electrophoretically separated,
deglycosylated native protein is accounted for by its
high proline content. Proteins with a high percentage of
proline typically show anomalous molecular sizes when
estimated on the basis of SDS-PAGE separations [212].
The recombinant antigen (rAg2/Pra) was expressed by
E. coli and shown to elicit both T cell and antibody
responses in patients with coccidioidomycosis [213/
215]. Immunization of BALB/c mice with rAg2/Pra
plus Freund’s adjuvant protected the animals against
i.p. challenge with 50 arthroconidia of C. posadasii ,
based on reduction of the fungal burden in the lungs
and spleen at 14 days post-infection [216]. CFUs in the
immunized mice were reduced by 2/2.5 log10 units
compared to the controls. Northern blot analysis of
AG2/PRA gene expression revealed that levels of
specific mRNA increased during stages of spherule
maturation [217], which correlated with the immuno-
localization of the antigen in the parasitic cell wall
[218]. In addition, little allelic diversity was detected in
the gene isolated from multiple strains of C. posadasii ,
suggesting that the rAg2/Pra vaccine should provide
comparable protection against a wide range of isolates.
This same antigen was also expressed in bacteria as a
glutathione-S-transferase (GST) fusion protein and
demonstrated protection against i.p. challenge in
BALB/c mice as assessed by decreased fungal burden
[130]. However, in a survival experiment, BALB/c mice
immunized with this recombinant antigen failed to
show protection compared to control mice during a 30-
day period post-challenge [130].
These contradictory results of the protective efficacy
of the recombinant Ag2/Pra in BALB/c mice have
raised doubts about the durability of protection
afforded by this immunogen. Recent studies have
suggested that the protective epitopes of Ag2/Pra are
contained within the N-terminal region of the protein
(amino acids 1/106), including the putative, 18-residue
signal peptide [219,220]. BALB/c mice immunized with
a plasmid vector-expressed N-terminal fragment of
Ag2/Pra and challenged via the intraperitoneal route
showed reduced fungal burden in their lungs and spleen
compared to non-immunized control animals 130, 220.
On the other hand, BALB/c mice which were adminis-
tered the same genetic vaccine and then challenged by
the pulmonary route showed no significant reduction
of fungal burden in their lungs, and their survival rate
was the same as control animals [130,220]. It appears
that both the recombinant protein and DNA formula-
tions of the Ag2/Pra vaccine provide early protection to
BALB/c mice against coccidioidomycosis, but fail to
sustain protection against pulmonary infection when
the animals are challenged with approximately 10/100
viable arthroconidia via the natural, i.n. route
[56,130,220]. The residual pulmonary infection in these
mice may provide a nidus for progressive disease and
death of the animals, or the development of persistent
pulmonary coccidioidomycosis commonly found in
humans [221]. A potential problem related to chronicity
of coccidioidal infection is that a shift from a protective
Th1 to a non-protective Th2 immunodominance may
occur, which could result in disseminated disease. It is
also possible that this shift in immunodominance could
be influenced by the acquired immunity induced during
the prophylactic vaccination regimen. The protective
N-terminal fragment of rAg2/Pra contains both Th1
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and Th2 epitopes. As in the case of the tuberculosis
BCG vaccine [222], the vaccination dose of rAg2/Pra
appears to define the Th1/Th2 nature of the immune
response. Immunization with low doses of rAg2/Pra
(0.5/1mg) may elicit primarily a Th1 response, while
higher doses (e.g., 5 mg) could induce mixed Th1/Th2
responses. These observations raise important ques-
tions about the durability of the rAg2/Pra vaccine that
still need to be addressed.
A second promising protective recombinant protein
is a wall-associated, GPI-anchored b-1, 3-glucanosyl-
transferase (rGel1) [190]. Antiserum raised against the
purified protein revealed that the antigen is expressed
on the surface of endospores, a stage of the parasitic
cycle which can be engulfed by phagocytes. The
recombinant protein is recognized in immunoblots by
sera from patients with confirmed Coccidioides infec-
tion, but not with human control sera. These data
indicate that Gel1 is a clinically relevant antigen.
Immunization with rGel1 plus CpG/IFA elicited a
protective response against coccidioidal infection via
the i.p. and i.n. routes in both BALB/c and C57BL/6
mice. Immune mice challenged intraperitoneally with
the pathogen showed approximately 3/4 log10 units
reduction in fungal burden in their lungs and spleen,
and when challenged by the i.n. route, 70% of the
immune mice survived compared to none of the non-
immunized animals.
As in the case of the recombinant Ag2/Pra vaccine,
we have shown that immunization of mice with
different amounts of rGel1 plus adjuvant results in
different degrees of protection (Fig. 6A/C). In contrast
to rAg2/Pra, however, we have revealed that vaccina-
tion of mice with the optimal amount of rGel1 (1 mg/
dose) resulted in the maintenance of elevated expres-
sion levels of IL-12 and IFN-g in BALFs and lung
tissue of infected mice (Fig. 6D, Fig. 8), which is
indicative of a sustained Th1 response.
A third recombinant protein that shows promise as a
vaccine candidate is the Coccidioides -specific antigen
(Csa) which we had isolated several years ago [48], but
only recently tested for its ability to protect mice
against coccidioidal infection [223]. The recombinant
Csa protein was expressed by E. coli and used as a
vaccine in combination with rAg2/Pra expressed by
Saccharomyces cerevisiae. C57BL/6 mice were immu-
nized intradermally with the combined vaccine plus
CpG/MPL adjuvant. Survival experiments showed that
rCsa/rAg2/Pra-immunized mice challenged intrana-
sally with a lethal inoculum of Coccidioides showed
90% survival at 60 days post-infection compared to
none of the infected animals immunized with adjuvant
alone (P B/0.0003). Mice immunized with rCsa or
rAg2/Pra alone plus adjuvant showed 30% and 60%
survival, respectively. Multivalent recombinant vac-
cines may enhance protective immunity against cocci-
dioidomycosis. It can be argued that such a vaccine may
increase the probability of induction of an appropriate
immune response in humans that leads to sequestration
and clearance of the pathogen [224].
Most of the other recombinant antigens of Cocci-
dioides which have been produced and tested to date
have failed to meet the benchmarks of protection
established in murine vaccine trials using rAgs/Pra
and rGel1, and are no longer considered candidates
for a human vaccine. These include the first purified
recombinant T-cell-reactive protein of Coccidioides
tested in a murine model [225], a heat shock protein
(rHsp60] [226], and a spherule outer wall glycoprotein
(rSOWgp) [103,121].
DNA vaccines against coccidioidomycosis which
have been tested to date provide consistently better
protection than recombinant protein vaccines
[109,130,220]. This was well illustrated in mice immu-
nized with recombinant urease (rUre) protein vs. the
URE DNA vaccine [189]. The maximum survival
observed in BALB/c mice immunized with the recom-
binant protein/CpG/IFA was 40%, while 80% of the
animals survived after immunization with the pSecTa-
g2A.URE plasmid construct. The apparent strong,
polarized Th1-type CD4 and CD8 responses in-
duced in mice by this DNA vaccine, coupled with its
adjuvant activity, provide a cogent argument that DNA
vaccination is a promising new approach for immuno-
prophylaxis against coccidioidomycosis. DNA vaccines
are relatively easy to produce and less expensive than
recombinant protein vaccines, do not require sophisti-
cated purification schemes or a cold chain for storage,
and can be used for repeated boosting [227]. However,
evidence from clinical trials suggests that DNA vaccines
have failed to induce the same level of robust and
broad-based immune responses in primates, including
humans, that have been reported in mice [227,228]. To
date, no DNA vaccines have been approved for general
human application in the U.S.
The Valley Fever Vaccine Project / a
cooperative research effort
A consortium of researchers affiliated with five aca-
demic institutions in the United States have focused
their efforts on development of a prophylactic vaccine
against coccidioidomycosis. Much of the progress made
over the last five years towards this goal has been the
result of the integrated research activities of the
consortium. An exciting approach to new vaccine
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discovery which involves cDNA expression library
immunization (ELI) is underway in the Cox laboratory
(University of Texas Health Sciences Center, San
Antonio) [229]. A Coccidioides spherule-phase cDNA
library containing 800/1000 genes was divided into 10
pools, and each was tested for its protective efficacy in
BALB/c mice against i.p. challenge with a lethal
inoculum of the pathogen. Sequential fractionation of
protective pools yielded a single clone, designated ELI-
Ag1. The gene has been sequenced and expressed, and
is under investigation as a vaccine candidate.
Our research group has cooperated with the Kirk-
land laboratory (Veterans Medical Research Founda-
tion, San Diego) and Gardner laboratory (The Institute
for Genomic Research [TIGR]) on use of the partial
genome database of Coccidioides for the identification
of genes that encode homologs of reported wall-
associated proteins [103] and parasitic phase-specific
antigens [230]. Our rationale for these discovery efforts
is that some of the gene products may be immunogenic
and exposed to the host immune system during the
parasitic cycle. As discussed above, studies of candidate
vaccines against coccidioidomycosis have indicated that
the most protective antigens are parasitic cell wall
proteins. We used the computer program BLASTx [231]
to perform conceptual translations of nucleotide se-
quences in the C. posadasii genomic database, followed
by searches of the nonredundant protein database [232]
to find good alignments between the Coccidioides and
database sequences [190]. Glimmer is a computational
gene finder that has been helpful for Coccidioides gene
identification and genome annotation [233]. Genomic
studies have already contributed to the discovery of
new arrays of genes involved in cell wall formation in
Saccharomyces [234], expression of phase-specific anti-
gens in H. capsulatum [235], and virulence factors in
other microbial pathogens [236]. The analysis of single
genomes is no longer satisfactory; comparisons of
multiple genomes of pathogenic fungi (e.g., Candida
albicans, Aspergillus fumigatus, Cryptococcus neofor-
mans, H. capsulatum , Blastomyces dermatitidis ) pro-
vide insights into conserved or unique families of
proteins and functional domains, improve the precision
of annotation, and permit identification of novel
immunogens which can be tested as vaccine candidates
[237].
Crude subcellular vaccines against coccidioidomyco-
sis have been reported [206,238]. Although these have
promise because of their protective nature (e.g., Fig.
9A), they are unlikely to transition to clinical trial
because the immunogenic components are undefined.
However, proteomic methods are now at hand which
can potentially overcome this problem [239]. Two
dimensional-polyacrylamide gel electrophoresis (2D-
Fig. 9 Application of proteomics to vaccine
discovery. (A). Survival plot of BALB/c mice
immunized subcutaneously with a Triton X-
114 detergent extract of an endosporulating
spherule homogenate (TX114-DF; 14 mg x2)
plus adjuvant (CpG/IFA) and challenged by
the intranasal route with 90 arthroconidia (C.
posadasii ; strain C735). Control mice were
immunized with adjuvant alone. The differ-
ence in percent survival between these two
groups is significant. (B). 2D-PAGE separa-
tion of the TX114-DF immunogen, showing a
major protein (circled) which was isolated
and subjected to trypsin digestion. (C). Re-
presentative collision-induced dissociation
(CID) spectrum generated by tandem mass
spectrometric analysis of the peptides released
from the digested protein in (B). The peptide
sequence in (C) matches the reported se-
quence of a Coccidioides aspartyl protease
(GenBank accession number AF162132).
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PAGE) is used first to separate the total protein
fraction (Fig. 9B). Isolated proteins excised as gel plugs
are then subjected to in-gel trypsin digestion. Tandem
mass spectrometry (MS) is subsequently employed to
obtain amino acid sequences of the eluted peptides. The
sequence data obtained from the resulting collision-
induced dissociation (CID) spectra (Fig. 9C) can be
used to search for sequence matches in the translated
Coccidioides protein database. This approach to the
systematic analyses of potential immunogenic compo-
nents of a TritonX-114 detergent extract of the spherule
wall fraction has resulted in the identification of a 45-
kDa aspartyl protease (Asp1). This same protein was
previously isolated in the Pappagianis laboratory
(University of California at Davis) from a soluble
vaccine prepared from formalin-killed spherules of
Coccidioides [240]. The deduced protein sequence of
the ASP1 gene revealed 83.2% similarity to the amino
acid sequence of a wall-associated aspartyl protease of
A. fumigatus [241]. Homologs of the C. posadasii Asp1
have also been reported in C. neoformans (F. Dromer,
Pasteur Institute, per comm.) (77.8% sequence similar-
ity), and Shistosoma japonicum [242,243] (66.9% se-
quence similarity). In both cases, the aspartyl protease
homologs have been shown to be T-cell reactive and
suggested to be candidate vaccines against the respec-
tive microbial infection. Preliminary studies in our
laboratory have shown that rAsp1 of C. posadasii
protects C57BL/6 mice against a lethal i.n. challenge of
the fungus. Compositional and structural studies of the
proteome of Coccidioides represent the next frontier of
research on this pathogen, and could lead to the
discovery of the optimal vaccine which provides potent
and durable protection against coccidioidomycosis.
Summary
Coccidioides is a formidable human pathogen which is
capable of establishing a life-threatening respiratory
disease in immunocompetent, healthy individuals. Na-
ı̈ve, adult BALB/c mice are highly susceptible to
coccidioidomycosis when challenged by the intranasal
route (B/10 arthroconidia establish disseminated dis-
ease and can be lethal). BALB/c mice immunized
subcutaneously with a live, avirulent mutant strain of
C. posadasii , which was generated by disruption of a
single chitin synthase gene, were protected against an
intranasal challenge with 100 viable arthroconidia of
the highly virulent, parental strain (C735). The pheno-
type of the Dchs5 mutant was characterized by aberrant
hyphae both in vitro and in vivo. The results of this
protection experiment demonstrate that successful
vaccination against coccidioidal infection of a suscep-
tible host challenged via the natural route with a lethal
inoculum is possible, and that protective antigens are
expressed by the saprobic phase and shared with the
parasitic phase in vivo. This immunized mouse provides
a model for examination of the host protective response
to Coccidioides infection. The murine model permits
studies of the phenotype of host cells involved in
sequestration and clearance of the pathogen, and
investigations of the expression of signal molecules
(cytokines, chemokines, chemokine receptors) involved
in the chemotaxis and activation of these cells during
the innate and acquired immune response. We suggest
that the results of these experiments will contribute
significantly to the development of a human vaccine
against coccidioidomycosis.
Although it is possible that a live, avirulent strain of
Coccidioides could be developed as a human vaccine, it
is more likely that a well-defined, recombinant protein-
based vaccine would be approved by regulatory boards
in the U.S. and accepted by volunteers in clinical trials.
Therefore, the focus of our studies of candidate
vaccines has been the identification of purified antigens
which elicit potent and durable host protective response
against Coccidioides infection. The lead vaccine candi-
dates include rAg2/Pra, rGel1, and rCsa/rAg2/Pra.
Potential candidates are in early stages of evaluation
[e.g., recombinant protein expressed by ELI-Ag1 [229],
and rAsp1]. Controversial issues related to the dur-
ability of protection afforded by vaccination with rAg2/
Pra, especially in BALB/c mice, raise concerns about
the use of this antigen in a human vaccine trial. Both
rAg2/Pra and rGel1 require further evaluation in
murine models to determine whether vaccine protocols
using these separate recombinant proteins plus CpG/
MPL can induce long-lasting protection and clearance
of the pathogen. Early results of the protective efficacy
of the combined rCsa/rAg2/Pra vaccine are very
promising, and suggest that combinations of other
recombinant proteins currently at hand may be equally
or even more protective against coccidioidal infection.
However, in spite of the promising results of immuniza-
tion with rCsa/rAg2/Pra, there is a paucity of
immunological data on the mechanisms of action of
this combined recombinant vaccine in C57BL/6 mice,
and concerns that it may not provide the same level of
protection to a host with a Th2-biased response (e.g.,
BALB/c mice). It would be premature to claim that a
vaccine against coccidioidomycosis is in hand. The
benchmark of a successful vaccine has been established
by the results of immunization of mice with the live,
avirulent Dchs5 mutant strain; 100% survival of BALB/
c mice beyond 45 days post-challenge, and sterility of
their body organs. Significant progress has been made
– 2004 ISHAM, Medical Mycology, 42, 189/216
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toward the production of a coccidioidomycosis vaccine;
we believe that generation of a successful, recombinant
prophylactic human vaccine against this fungal patho-
gen is achievable.
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